EFFECTOR Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From the Primary Analysis of the Randomized Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-small Cell Lung Cancer
EFFECTOR Therapeutics的股價走低。該公司公佈了Tomivosertib與Pembrolizumab聯合用於非小細胞肺癌的隨機2期KICKSTART試驗的初步分析結果